Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.

Abstract

A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.

• Authors: F A László, L Baláspiri
• Journal: Acta medica Hungarica (Acta Med Hung) Vol. 43 Issue 3 Pg. 333-9 ( 1986) ISSN: 0236-5286 [Print] Hungary
• PMID: 3588172 (Publication Type: Journal Article)

Chemical References

• Vasopressins
• Arginine Vasopressin
• 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(O-ethyl-Tyr)-4-Val-arginine vasopressin
• Deamino Arginine Vasopressin

Topics

• Animals
• Arginine Vasopressin (administration & dosage, analogs & derivatives)
• Deamino Arginine Vasopressin
• Disease Models, Animal
• Inappropriate ADH Syndrome (prevention & control)
• Male
• Rats
• Vasopressins (antagonists & inhibitors)
• Water Intoxication (prevention & control)